Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
danusertib
Description:
Danusertib is an anticancer drug that inhibits Aurora kinases and other protein kinases, investigated for treatment of solid tumors.
Related topics:
Chronic Myeloid Leukemia Treatments (18%),
Microtubule and mitosis dynamics (15%)
Wikidata ID:
wiki/Q27076981
OpenAlex ID:
keywords/danusertib
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
2018
·
Federico Rossari
, Filippo Minutolo
, et al.
·
Journal of Hematology & Oncology
·
418
PDF
The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability
2018
·
Hai Wang
, Lin Tian
, et al.
·
Cancer Cell
·
158
PDF
Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors
2009
·
Neeltje Steeghs
, Ferry A.L.M. Eskens
, et al.
·
Journal of Clinical Oncology
·
115
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
2012
·
Georg E Winter
, Uwe Rix
, et al.
·
Nature Chemical Biology
·
100
PDF
A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
2009
·
Roger B. Cohen
, Suzanne F. Jones
, et al.
·
Clinical Cancer Research
·
94
PDF
Danusertib, an aurora kinase inhibitor
2012
·
Hielke J Meulenbeld
, Ron HJ Mathijssen
, et al.
·
Expert Opinion on Investigational Drugs
·
84
Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure
2012
·
Hielke J. Meulenbeld
, Jean P. Bleuse
, et al.
·
British Journal of Urology
·
77
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
2015
·
G. Borthakur
, H. Dombret
, et al.
·
Haematologica
·
63
Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study
2014
·
P. Schöffski
, B. Besse
, et al.
·
Annals of Oncology
·
62
PDF
Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor
2009
·
Artur Gontarewicz
, Tim H. Brümmendorf
·
Recent results in cancer research/Recent Results in Cancer Research
·
56
Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells
2015
·
Dan Zi
, Zhi-Wei Zhou
, et al.
·
International Journal of Molecular Sciences
·
54
PDF
The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing
2012
·
Stefan O. Ochiana
, Vidya Pandarinath
, et al.
·
European Journal of Medicinal Chemistry
·
53
Inhibition of Aurora kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in human leukemia cells
2016
·
Si-Jia He
, Li-Ping Shu
, et al.
·
Cancer Letters
·
52
In vitro drug metabolism by C-terminally truncated human flavin-containing monooxygenase 3
2011
·
Gianluca Catucci
, Gianfranco Gilardi
, et al.
·
Biochemical Pharmacology
·
49
PDF
Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies
2017
·
Hai Wang
, Lin Tian
, et al.
·
Nature Communications
·
48
PDF
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
2015
·
Stine Hole
, Astrid M. Pedersen
, et al.
·
Breast Cancer Research and Treatment
·
48
Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro
2011
·
Stefan Balabanov
, Artur Gontarewicz
, et al.
·
PLoS ONE
·
48
PDF
In situ electrochemical evaluation of dsDNA interaction with the anticancer drug danusertib nitrenium radical product using the DNA-electrochemical biosensor
2015
·
Victor Constantin Diculescu
, Ana Maria Oliveira-Brett
·
Bioelectrochemistry
·
47
Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .
2009
·
Jorge Cortes-Franco
, Hervé Dombret
, et al.
·
Blood
·
44
An Integrated Chemical Biology Approach Identifies Specific Vulnerability of Ewing's Sarcoma to Combined Inhibition of Aurora Kinases A and B
2011
·
Georg E. Winter
, Uwe Rix
, et al.
·
Molecular Cancer Therapeutics
·
43
Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model
2012
·
Katharina Fraedrich
, Jörg Schrader
, et al.
·
Clinical Cancer Research
·
41
Drug-induced senescence by aurora kinase inhibitors attenuates innate immune response of macrophages on gastric cancer organoids
2024
·
Ruixin Yang
, Wingyan Kwan
, et al.
·
Cancer Letters
·
36
Escherichia coli Overexpressing a Baeyer-Villiger Monooxygenase from Acinetobacter radioresistens Becomes Resistant to Imipenem
2015
·
Daniela Minerdi
, Ivan Zgrablic
, et al.
·
Antimicrobial Agents and Chemotherapy
·
36
PDF
Identification of Myb-binding Protein 1A (MYBBP1A) as a Novel Substrate for Aurora B Kinase
2010
·
Claudia Perrera
, Riccardo Colombo
, et al.
·
Journal of Biological Chemistry
·
33
PDF
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants
2018
·
Nene N. Kalu
, Tuhina Mazumdar
, et al.
·
Cancer Letters
·
32
Show more works
View as search
Works count:
128
Citation count:
2,314
Year
Topic
Type